Daniel Goldman, Representative
sell disclosed on 19 May 2023 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +7.7%
Public company research profile
This public-disclosure research profile is not investment advice. It summarizes historical public filings, source links, confidence context, and hypothetical outcomes so readers can verify the evidence themselves.
Company research history
Sabra Health Care REIT, Inc. (SBRA)
Source-transparent disclosure history for this company, built from public CopyWindow signals and previous hypothetical outcomes.
4 disclosures
2 insiders
0 cluster signals
+3.2% avg. 30d outcome (4 of 4)
Company facts
- Ticker / ISIN
- SBRA / Not available
- Exchange
- Not available
- Country
- US
- Sector
- Not available
Disclosure history
Daniel Goldman, Representative
buy disclosed on 17 Apr 2023 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -1.2%
Christopher L. Jacobs, Representative
sell disclosed on 12 Dec 2022 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +4.0%
Christopher L. Jacobs, Representative
buy disclosed on 28 Jul 2022 via House STOCK Act disclosures
- Transaction value
- US$15,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +2.3%